Search
Linagliptin
go.drugbank.com/drugs/DB08882ApprovedInvestigationalLinagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes [L9557]. … Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding[A37050
Mixtures: Trijardy XR, Trijardy XRCategories: Drugs Used in Diabetes, DPP-IV InhibitorsDasiglucagon
go.drugbank.com/drugs/DB15226Approved[L39195] Even with close monitoring of blood glucose levels, it is not always possible to prevent severe hypoglycemic events in patients with diabetes, and children are particularly at risk for experiencing … [L39190] It consists of 29 amino acids similar to endogenous glucagon; however, it contains seven substituted amino acids for improved physical and chemical stability in its drug formulation.
Fluvoxamine
go.drugbank.com/drugs/DB00176ApprovedInvestigationalThough it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. … It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.
Categories: Antidepressive Agents Indicated for Depression, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: VERLIN TABLETAS X 50 MGBaloxavir marboxil
go.drugbank.com/drugs/DB13997ApprovedInvestigational[A251760] Baloxavir marboxil was first globally approved in Japan in February 2018,[A39895] followed by the US approval in October, 2018. … Baloxavir marboxil is an antiviral drug used to treat influenza. More specifically, it is a first-in-class cap-dependent endonuclease inhibitor that works to block influenza virus proliferation.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseLindane
go.drugbank.com/drugs/DB00431ApprovedWithdrawnIn Canada, Lindane is not recommmended as a first-line therapy due to reports of resistance, neurotoxicity, and bone marrow suppression, but has been approved by the FDA as a second-line therapy for topical … Lindane is still allowed for pharmaceutical use until 2015.
Categories: Compounds used in a research, industrial, or household settingGastric intrinsic factor
go.drugbank.com/drugs/DB09349ApprovedIntrinsic factor is not currently available in any FDA or Health Canada approved products. … on in the small intestine.
Mixtures: EnLyte Extra-LNDaclatasvir
go.drugbank.com/drugs/DB09102ApprovedInvestigationalWithdrawnIt is marketed under the name DAKLINZA and is contained in daily oral tablets as the hydrochloride salt form . … The most common critical NS5A amino acid substitutions that led to reduced susceptibility to daclatasvir therapy occured at position Q30 (Q30H/K/R) and M28 in genotype 1a patients and Y93H in genotype
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseProducts: I-HEP CLASTAVIR 30, I-HEP CLASTAVIR 60Idelalisib
go.drugbank.com/drugs/DB09054ApprovedInvestigationalFor the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other … In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils
Categories: Class Ia Phosphatidylinositol 3-Kinase, antagonists & inhibitorsBendazac
go.drugbank.com/drugs/DB13501ApprovedWithdrawnBendazac, however, has since been withdrawn or discontinued in various international regions due to its capability or risk for eliciting hepatotoxicity [A39891, A39892, A39893, L4778] in patients although … a small handful of regions may continue to have the medication available for purchase and use either as a topical anti-inflammatory/analgesic cream or eye drop formulation.
Categories: Antiinflammatory Preparations, Non-Steroids for Topical Use, Topical Products for Joint and Muscular PainHyoscyamine
go.drugbank.com/drugs/DB00424ApprovedInvestigational[A228713] Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimuscarinic properties. … [L31548,L31553] Although hyoscyamine is marketed in the United States, it is not FDA approved.[L31548,L31553]
Mixtures: UR N-C Urinary Antiseptic, Re-PB HyosCategories: Drugs for Functional Gastrointestinal Disorders